SCHOFIELD, Wis., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience Inc. (OTCBB:PMBS) announced today that it has received an initial series of purchase orders for its new over-the-counter migraine medication, LipiGesic®M with the second largest chain drug retailer in the United States, CVS. This follows a recent announcement that LipiGesic®M is now available nationwide at Walgreens, the largest chain of drug stores in the United States.
CVS has over 7,000 locations in the United States which will almost double the amount of stores that will carry their featured product, LipiGesic®M, bringing the total number of stores to over 14,700. "This is a very exciting time for our Company," said Russ Mitchell, CEO of PuraMed BioScience. "In just the past few months, we have been able to announce purchase orders with the #1 and #2 chain drug stores in the U.S. Adding 7,000 CVS stores nationwide will nearly double our national exposure and dramatically affect our ability to reach even more migraine sufferers. While we are elated to have achieved this impressive level of national distribution, we will continue to actively pursue additional retail opportunities worldwide."
PuraMed expects to ship product to CVS in the beginning of January 2012 and anticipates it will begin to appear on shelves sometime around the end of January.
In addition to purchase orders of LipiGesic®M from both Walgreens and CVS, PuraMed also recently announced that three top headache researchers performed a study of LipiGesic®M that was published in the top-tier medical journal, Headache Volume 51, Number 7, July/August 2011. This study demonstrated that the product was highly effective and recommended LipiGesic®M as a first line treatment for migraines to the medical community.
PuraMed BioScience, Inc. plans to provide more information as it becomes available.
About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract. LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.
For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com/" target="_top" rel="nofollow">www.PuraMedBioScience.com, and join the Company's group page on Facebook by searching "PuraMed BioScience".
Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.